Clinical end points of therapy for patients with mild community-acquired pneumonia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18986280.
- Also identified by DOI 10.1086/591395.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Approximately 80% of patients with community-acquired pneumonia receive treatment as outpatients. The question is what are valid, reproducible, and quantifiable clinical end points that can be used in prospective clinical trials of the safety and efficacy of antibacterials. Patient-reported outcomes and measurements of time to end point are reasonable methods that, according to the limited data available, appear to work in clinical trials of therapy for mild-to-moderate community-acquired pneumonia among outpatients.
Medical subject headings
- Anti-Bacterial Agents
- Community-Acquired Infections
- Pneumonia, Bacterial